Kenneth G. Linden

Dr. Kenneth G. Linden


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2005 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JSJoannie D. Sun
Joannie D. Sun
KLKenneth G. Linden
Kenneth G. Linden

1 May 2014 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
KLKenneth G. Linden
Kenneth G. Linden
SLSancy A. Leachman
Sancy A. Leachman
JZJonathan S. Zager
Jonathan S. Zager
JJJames G. Jakowatz
James G. Jakowatz
JVJaye L. Viner
Jaye L. Viner
FMFrank L. Meyskens
Frank L. Meyskens
On the basis of large cardiovascular clinical trials of lipid-lowering agents that showed a considerable decrease in the incidence of primary melanomas in the active agent arm, we have carried out a randomized, double-blind clinical trial examining the impact of lovastatin on various biomarkers of melanoma pathogenesis. Subjects with at least two clinically atypical nevi were randomized to receive oral lovastatin or placebo for a 6-month period. Clinical, histopathologic, and molecular biomarkers were evaluated for change in the two groups. Eighty subjects were randomized, evaluable, and included in the analyses. Lovastatin showed no benefit in comparison with placebo in the primary endpoint of decreasing the level of histopathologic atypia, nor in any of the secondary endpoints of decreasing clinical atypia, impact on nevus number, nor in showing significant changes in any of the molecular biomarkers. There were no significant differences in adverse event profiles for lovastatin compared with placebo. The lovastatin arm did show a significant and considerable decrease in total serum cholesterol and serum low-density lipoprotein (LDL) levels compared with placebo, an expected result. This finding bolsters confidence in subject compliance. Given the results of this trial, it is concluded that if lovastatin were to lower the incidence of melanoma, it would appear not to be doing so by reversing atypia of precursor atypical nevi over the 6-month time frame studied. Further research into the pathogenesis of melanoma and in other potential chemopreventive agents is needed. Cancer Prev Res; 7(5); 496–504. ©2014 AACR.

1 March 2003 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
RBRonald J. Barr
Ronald J. Barr
KLKenneth G. Linden
Kenneth G. Linden
GRGennady Rubinstein
Gennady Rubinstein
KCKenneth A. Cantos
Kenneth A. Cantos
DUE TO increasing numbers of biopsy specimens of partially shaved nevi received in our dermatopathology laboratory, we thought that it would be interesting and important to determine the incidence of histologic heterogeneity within atypical nevi. It is generally appreciated that nevi may exhibit clinical and histologic atypia.1-3 For this study, sections of 298 histologically atypical nevi were reviewed to evaluate the heterogeneity of atypia within individual nevi in a more precise fashion. Heterogeneity of atypia is important because biopsy specimens of partially removed nevomelanocytic neoplasms may not be representative of the entire lesion.

1 December 2004 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
KLKenneth G. Linden
Kenneth G. Linden

15 September 2023 in JAAD Case Reports
Verified
Journal Article
Open access
CKColin M. Kincaid
Colin M. Kincaid
ASAjay N. Sharma
Ajay N. Sharma
BLBonnie A. Lee
Bonnie A. Lee
LPLauren C. Pinter-Brown
Lauren C. Pinter-Brown
JSJanellen Smith
Janellen Smith
NMNatasha Mesinkovska
Natasha Mesinkovska

1 May 2018 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
KLKenneth G. Linden
Kenneth G. Linden